Lataa...
Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed rechallenge with...
Tallennettuna:
| Julkaisussa: | Intern Med |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Japanese Society of Internal Medicine
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7008039/ https://ncbi.nlm.nih.gov/pubmed/31534079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.2597-18 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|